gliflozin
Gliflozin, also known as canagliflozin, is a medication used to treat type 2 diabetes and chronic kidney disease. It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the bloodstream.
Gliflozin was first approved for use in Japan in 2013 and has since been approved in numerous
The mechanism of action of gliflozin involves the inhibition of SGLT2, a protein in the kidneys that
Common side effects of gliflozin include increased urination, genital fungal infections, and thirst. In addition, gliflozin